Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis.

Chen, Chao; An, Li; Cheng, Ying; Luo, Xianwen; Li, Zixiong; Liu, Xiufeng

Chen, Chao; An, Li; Cheng, Ying; Luo, Xianwen; Li, Zixiong; Liu, Xiufeng.

Afiliación

Chen C; Department of Medical Oncology of PLA Cancer Center, Jinling Hospital, Nanjing, China.
An L; Department of Gerontology, The Affiliated Zhongda Hospital of Southeast University, Nanjing, China.
Cheng Y; Department of Medical Oncology of PLA Cancer Center, Jinling Hospital, Nanjing, China.
Luo X; Department of Medical Oncology of PLA Cancer Center, Jinling Hospital, Nanjing, China.
Li Z; Department of Medical Oncology of PLA Cancer Center, Jinling Hospital, Nanjing, China.
Liu X; Department of Medical Oncology of PLA Cancer Center, Jinling Hospital, Nanjing, China.

Front Oncol ; 10: 1404, 2020.

Article en En | MEDLINE | ID: mdl-32983970

Palabras clave

chemotherapy; hepatitis B virus; hepatocellular carcinoma; nivolumab; programmed cell death protein 1; tyrosine kinase inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2020 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google